Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itolizumab in Systemic Lupus Erythematosus and Lupus Nephritis
NCT04128579Phase 1Completed
- Sponsor
- Biocon
- Start
- Oct 2019
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of itolizumab in systemic lupus erythematosus (SLE) and lupus nephritis (LN) (2 cohorts), sponsored by Biocon. Primary endpoint: Number of Treatment Emergent Adverse Events at Day 253. Started Oct 2019; status: completed.
02
Drugs
itolizumab
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on NCT04128579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04128579.